Peptide research profile

Follistatin-315

Explore Follistatin-315, a circulating activin-binding protein studied for muscle growth, fibrosis control, and tissue repair.

  • Growth hormone signaling
Source review pending1 links under reviewEducational context

Dosing literacy

Dosing & scaling, explained

The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.

Recorded amount context

Mass amounts available for comparison

  1. Lower range100 mcg
    Dose

    Recorded example with no verified study backing; shown for amount literacy only.

  2. Mid range300 mcg
    Dose

    Recorded example with no verified study backing; shown for amount literacy only.

Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.

Schedule literacy

No independently verified schedule

Evidence context

No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.

Research best practices

Storage, handling and interpretation

Product identity

Verify the exact compound, formulation and amount against the product label or certificate before calculation.

Storage & handling

Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.

Prepared solutions

Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.

Research orientation

What researchers are exploring

These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.

  • 01

    Muscle Growth Research

    Myostatin inhibition and performance insights

  • 02

    Inflammation & Fibrosis

    Autoimmune, pulmonary, and radiotherapy studies

  • 03

    Vascular & Organ Support

    Endothelial recovery and renal protection

  • 04

    Biomarkers & Protein Engineering

    Disease monitoring and synthetic derivatives

  • 05

    Summary

    Research considerations

Evidence map

What is known—and what still needs verification

Available context is organized without assigning unsupported study models or evidence grades.

  • Source review pending

    Muscle Growth Research

    Myostatin inhibition and performance insights

  • Source review pending

    Inflammation & Fibrosis

    Autoimmune, pulmonary, and radiotherapy studies

Recorded protocol library

Amounts recorded for Follistatin-315

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Dose · lower endpoint

    100 mcg

    Sign in for schedule, duration and source context.

  • 02

    Dose · upper endpoint

    300 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Sequence
GNCWLRQAKN GRCQVLYKTEL SKEECCSTGR LSTSWTEEDV NDNTLFKWMIF NGGAPNCIPCK ETCENVDCGP GKKCRMNKKN KPRCVCAPDCS NITWKG PVCGLDGKTYR NECALLKARCK EQPELEVQYQG RCKKTCRDVFC PGSSTCVVDQT NNAYCVTCNRI CPEPASSEQYL CGNDGVTYSSA CHLRKATCLLG RSIGLAYEGKC IKAKSCEDIQC TGGKKCLWDFK VGRGRCSLCDE LCPDSKSDEP VCASDNATYA SECAMKEAACS SGVLLEVKHS GSCNSISEDTE EEEDE DQDYSFPISSILEW
Molecular Weight
~35 kDa (mature protein)
PubChem CID
178101631 (full-length follistatin)
Synonyms
Activin-binding protein, FSH-suppressing protein, FST-315

Important limitations

  • Individual claims and source links have not yet completed editorial verification.
  • Evidence level, applicable study model, formulation, route and population remain unassigned.

Source review

1 links awaiting verification

  1. Source link · pmc.ncbi.nlm.nih.govVerification pending · Source review pending

Related profiles